

Pharmaquant International Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 April 2025

Pharmaquant International Limited

CONTENTS

	Page
Directors' Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 9

Pharmaquant International Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Miss Namrata Bhattacharyya
Director

Mr Ronan Thomas Mahon
Director

23 January 2026

Pharmaquant International Limited

BALANCE SHEET

as at 30 April 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	47,221	-
Current Assets			
Debtors	8	30,188	4,274
Cash and cash equivalents		91,382	24,464
		121,570	28,738
Creditors: amounts falling due within one year	9	(89,221)	(18,639)
Net Current Assets		32,349	10,099
Total Assets less Current Liabilities		79,570	10,099
Creditors: amounts falling due after more than one year	10	-	(10,000)
Net Assets		79,570	99
Capital and Reserves			
Called up share capital presented as equity	12	100	100
Retained earnings		79,470	(1)
Equity attributable to owners of the company		79,570	99

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Pharmaquant International Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 23 January 2026 and signed on its behalf by:

Miss Namrata Bhattacharyya
Director

Mr Ronan Thomas Mahon
Director

Pharmaquant International Limited
STATEMENT OF CHANGES IN EQUITY

as at 30 April 2025

	Called up share capital €	Retained earnings €	Total €
At 1 May 2023	-	(3,396)	(3,396)
Profit for the financial year	-	3,395	3,395
At 30 April 2024	100	(1)	99
Profit for the financial year	-	79,471	79,471
At 30 April 2025	100	79,470	79,570

Pharmaquant International Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

1. General Information

Pharmaquant International Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 717739. The registered office of the company is Unit 312 Q-House, 76 Furze Road, Sandyford, Dublin 18. The principal activity of the company is that to provides Health Economics and Outcome research (HEOR) services to its customers. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight line
----------------------------------	---	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Pharmaquant International Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Turnover

The whole of the company's turnover is attributable to its market in Ireland and is derived from the principal activity of

4. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	625	-
Loss/(profit) on foreign currencies	6,253	-
	<u> </u>	<u> </u>

5. Interest payable and similar expenses	2025	2024
	€	€
Interest	356	-
	<u> </u>	<u> </u>

6. Employees

The average monthly number of employees, including directors, during the financial year was 5, (2024 - 3).

7. Tangible assets

	Fixtures, fittings and equipment	Total
	€	€
Cost		
At 1 May 2024	-	-
Additions	47,846	47,846
	<u> </u>	<u> </u>
At 30 April 2025	47,846	47,846
	<u> </u>	<u> </u>
Depreciation		
At 1 May 2024	-	-
Charge for the financial year	625	625
	<u> </u>	<u> </u>
At 30 April 2025	625	625
	<u> </u>	<u> </u>
Net book value		
At 30 April 2025	47,221	47,221
	<u> </u>	<u> </u>

Pharmaquant International Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

8. Debtors			2025	2024
			€	€
Trade debtors			-	787
Taxation			15,463	3,487
Prepayments			14,725	-
			30,188	4,274
9. Creditors			2025	2024
Amounts falling due within one year			€	€
Trade creditors			31,430	-
Taxation			54,791	3,927
Other creditors			-	6,043
Accruals			3,000	8,669
			89,221	18,639
10. Creditors			2025	2024
Amounts falling due after more than one year			€	€
Directors' loan accounts			-	10,000
11. Taxation			2025	2024
			€	€
Debtors:				
VAT			15,463	3,487
Creditors:				
Corporation tax			12,067	-
PAYE			42,724	3,927
			54,791	3,927
12. Share capital			2025	2024
			€	€
Description	Number of shares	Value of units		
Authorised				
Ordinary shares	100,000	€1.00 each	100,000	100,000
Allotted, called up and fully paid				
Ordinary shares	100	€1.00 each	100	100

The directors' and the secretary's interests in the shares of the company are as follows:-

Name	Class of Shares	Number Held At	
		30/04/25	01/05/24
Miss Namrata Bhattacharyya	Ordinary shares	100	20
Liviu Lungu	Ordinary shares	-	15
		100	35

Pharmaquant International Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

13. Income Statement

	2025	2024
	€	€
At 1 May 2024	(1)	(3,396)
Profit for the financial year	79,471	3,395
	<u>79,470</u>	<u>(1)</u>
At 30 April 2025	<u>79,470</u>	<u>(1)</u>

14. Capital commitments

The company had no material capital commitments at the financial year-ended 30 April 2025.

15. Directors' remuneration and transactions

	2025	2024
	€	€
Remuneration	86,016	30,433
Pension contributions	8,035	-
	<u>94,051</u>	<u>30,433</u>

The following amounts are repayable to the directors:

	2025	2024
	€	€
Miss Namrata Bhattacharyya	-	10,000
	<u>-</u>	<u>10,000</u>

16. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

17. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 23 January 2026.